Erlotinib (Tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer

P and T

Volumn 34, Issue 10, 2009, Pages 554-564

  Rocha Lima, Caio M ^a   Raez, Luis E ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

EGFR mutation; Erlotinib; Non small cell lung cancer; Pancreatic cancer

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PANITUMUMAB; PEMETREXED; PLACEBO;

ADVANCED CANCER; BLISTER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CORNEA PERFORATION; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG INHIBITION; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PANCREAS CANCER; PATIENT SELECTION; RASH; REVIEW; STEVENS JOHNSON SYNDROME; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 70450248381     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Tarceva (erlotinib), package insert. Melville, NY: OSI Pharmaceuticals Inc.; 2009.
2. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19(56):6550-6565. (Pubitemid 32197693)
3. Shepherd FA, Rodrigues Pereira J, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-132.
4. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25(15):1960-1966. (Pubitemid 46972777)
5. FDA. Drugs@FDA. Available at: www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed January 14, 2009.
6. National Comprehensive Cancer Network (NCCN). Drugs & Biologics Compendium. Available at www.nccn.org/professionals/drug-compendium/content/ contents.asp. Accessed January 13, 2009.
7. American Cancer Society. Cancer facts and figures 2009. Available at: www.cancer.org/downloads/STT/500809web.pdf. Accessed May 23, 2009.
8. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25(5):587-595. (Pubitemid 350002967)
9. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience (Abstract 2). J Clin Oncol 2008;26(May 20 Suppl).
10. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-1765.
11. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2007;13(10):2890-2896. (Pubitemid 46849563)
12. Jackman DM, Sequist LV, Cioffredi L, et al. Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib (Abstract 8035). J Clin Oncol 2008;26(May 20 Suppl).
13. Thatcher N, Chang A, Parikh P, et aL Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366(9496):1527-1537. (Pubitemid 41540110)
14. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21(12):2237-2246. (Pubitemid 46621858)
15. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003;290(16):2149-2158. (Pubitemid 37432975)
16. Iressa (gefitinib), package insert. Wilmington, DE: AstraZeneca; 2005.
17. Ramalingam S, Sandler AB. Salvage therapy for advanced non-small cell lung cancer: Factors influencing treatment selection. Oncologist 2006;11(6):655-665. (Pubitemid 43967620)
18. Clark GM, Zborowski DM, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006;7(6):389-394. (Pubitemid 44043548)
19. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21. J Clin Oncol 2006;24(24):3831-3837. (Pubitemid 46630729)
20. Groen H, Arrieta OG, Riska H, et al. The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC) (Abstract 19000). J Clin Oncol 2008;26(May 20 Suppl).
21. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23(25):5892-5899. (Pubitemid 46300205)
22. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25(12):1545-1552. (Pubitemid 46733081)
23. Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13(13):3913-3921. (Pubitemid 47037599)
24. FDA. Tarceva (erlotinib), May 2009. Available at www.fda.gov/Safety/ MedWatch/Safetylnformation/SafetyAlertsforHumanMedicalProducts/ucm150596.htm. Accessed June 11, 2009.
25. Spigel DR, Lin M, O'Neill V, Hainsworth JD. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced non-small cell lung cancer. Cancer 2008;112(12):2749-2755. (Pubitemid 351969220)
26. Allan S, Bosquee L, Franke A, et al. Efficacy of erlotinib in patients with advanced non-small-cell lung cancer relative to clinical characteristics: Subset analyses from the TRUST study (Abstract 8081). J Clin Oncol 2008;26(May 20 Suppl):444s.
27. Crinò L, Moyer M, Eberhardt W, et al. Second-line erlotinib in patients with advanced non-small-cell lung cancer: Results from a large, open-label study (Abstract 19002). J Clin Oncol 2008;26 (May 20 Suppl):706s.
28. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22(9):1589-1597. (Pubitemid 41079796)
29. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18(10):2095-2103. (Pubitemid 30324363)
30. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18(12): 2354-2362. (Pubitemid 30415821)
31. Wailoo A, Sutton A, Morgan A. The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: A systematic review and meta-analysis. Br J Cancer 2009;100(3): 436-441.
32. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 2004;22(5): 777-784. (Pubitemid 41103588)
33. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 2004;22(5):785-794. (Pubitemid 41103588)
34. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, V.2.2009. Available at: www.nccn.org/professionals/physician-gls/PDF/nscl.pdf. Accessed January 13, 2009.
35. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J Clin Oncol 2008;26(26):4268-4275.
36. Hirsch FR, Dziadziuszko R, Camidge DR, et al. Biomarker status correlates with clinical benefit: Phase 2 study of single-agent erlotinib (E) or E intercalated with carboplatin and paclitaxel (ECP) in an EGFR biomarker-selected NSCLC population (Abstract 11). J Thorac Oncol 2008;3(Suppl 4):S263-S305.
37. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12(3 Part 1):839-844. (Pubitemid 43259866)
38. Cortes-Funes H, Gomez C, Rosell R, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 2005;16(7):1081-1086. (Pubitemid 41418309)
39. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97(9):643-655. (Pubitemid 40812628)
40. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group study. J Clin Oncol 2005; 23(28):6838-6845. (Pubitemid 46260270)
41. Mok TS, Leong S, Liu X, et al. Gefitinib (g) vs. carboplatin/paclitaxel (c/p) in clinically selected chemonaïve patients with advanced non-small-cell lung cancer (NSCLC) in Asia (IPASS): Randomized, open-label, phase III study (Abstract). J Thorac Oncol 2008;3(11 Suppl 4):S263-S305.
42. Ramsey SD, Clarke L, Kamath TV, Lubeck D. Evaluation of erlotinib in advanced non-small cell lung cancer: Impact on the budget of a U.S. health insurance plan. J Manag Care Pharm 2006;12(6):472-478. (Pubitemid 47400588)
43. Carlson JJ, Reyes C, Oestreicher N, et al Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 2008;61(3):405-415.
44. Ramsey SD, Clarke L, Kamath TV, Lubeck D. Second-line and third-line chemotherapy for lung cancer: Use and cost. Am J Manag Care 2008;14(5):297-306. (Pubitemid 351705845)
45. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24(14):2137-2150. (Pubitemid 46655601)
46. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-98.
47. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363(9414):1049-1057.
48. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15(6):2403-2413.
49. Burris H 3rd, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: Targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 2008;13(3):289-298.
50. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20(15):3270-3275. (Pubitemid 34831525)
51. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006;8(Suppl 1):S7-S14.
52. Saltz L, Rubin MS, Hochster H et al. Acne-like rash predicts response in patients treated with cetuximab (IMC-225) plus irinotecan (CPT-11) in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) (Abstract 559). Clin Cancer Res 2001;7:3766s.
53. Danese MD, Reyes C, Northridge K, et al. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced nonresectable or metastatic pancreatic cancer. Clin Ther 2008;30(4):775-784. (Pubitemid 351689042)
54. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC (Abstract 8001). J Clin Oncol 2009;27(Suppl):15s.
55. National Institutes of Health. ClinicalTrials.gov. Available at www.clinicaltrials.gov. Accessed January 13, 2009.
56. Gumerlock PH, Pryde BJ, Kimura T, et al. Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung carcinoma (NSCLC) (Abstract 2661). J Clin Oncol 2003;22(May 20 Suppl).
57. Solit DB, She Y, Lobo J, et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2005;11(5):1983-1989. (Pubitemid 40471864)
58. Lee J-S, Ignacio J, Yu C-J, et al. FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as 1st-line treatment in patients with stage IIIB/IV non-small cell lung cancer (Abstract 8031). J Clin Oncol 2008;26(May 20 Suppl).
59. Winstead ER. Lung cancer and erlotinib: Which patients benefit? NCI Cancer Bull, 2008;5 (October 21, 2008). Available at www.cancer.gov/ ncicancerbulletin/NCI-Cancer-Bulletin-102108/page6. Accessed January 16, 2009.
60. Hainsworth J, Herbst R. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA) (Abstract). J Thorac Oncol 2008;3(11 Suppl 4):S263-S305.
61. Miller VA, O'Connor P, Soh C, et al. A randomized double-blind, placebo-controlled, phase III trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced recurrent, or metastatic non-small cell lung cancer (NSCLC) (Abstract LBA8002). J Clin Oncol 2009;27(Suppl):18s.
62. Duffy A, Kortmansky J, Schwartz GK, et al. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 2008;19(1):86-91.
63. Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007;25(30):4787-4792. (Pubitemid 350086482)